137 related articles for article (PubMed ID: 10754464)
1. Serum level of HER-2/neu in patients with gastric cancer: correlation with HER-2/neu overexpression in gastric carcinoma tissue.
Kono K; Naganuma H; Sekikawa T; Amemiya H; Takahashi A; Iizuka H; Matsumoto Y
Tumour Biol; 2000; 21(3):139-44. PubMed ID: 10754464
[TBL] [Abstract][Full Text] [Related]
2. Significance of TFF3 protein and Her-2/neu status in patients with gastric adenocarcinoma.
Xu CC; Yue L; Wei HJ; Zhao WW; Sui AH; Wang XM; Qiu WS
Pathol Res Pract; 2013 Aug; 209(8):479-85. PubMed ID: 23822993
[TBL] [Abstract][Full Text] [Related]
3. ADAM 10 is associated with gastric cancer progression and prognosis of patients.
Wang YY; Ye ZY; Li L; Zhao ZS; Shao QS; Tao HQ
J Surg Oncol; 2011 Feb; 103(2):116-23. PubMed ID: 21259244
[TBL] [Abstract][Full Text] [Related]
4. Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinoma.
Ardizzoni A; Cafferata MA; Paganuzzi M; Filiberti R; Marroni P; Neri M; Fontana V; Nicoló G; Perdelli L; Stampino CG; Rosso R; Puntoni R
Cancer; 2001 Oct; 92(7):1896-904. PubMed ID: 11745263
[TBL] [Abstract][Full Text] [Related]
5. Her-2/neu assessment for gastric carcinoma: validation of scoring system.
Mrklic I; Bendic A; Kunac N; Bezic J; Forempoher G; Durdov MG; Karaman I; Prusac IK; Pisac VP; Vilovic K; Tomic S
Hepatogastroenterology; 2012; 59(113):300-3. PubMed ID: 22260838
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathologic Implications of Eukaryotic Initiation Factor 3f and Her-2/neu Expression in Gastric Cancer.
Cheng Y; Zhou J; Li H
Clin Transl Sci; 2015 Aug; 8(4):320-5. PubMed ID: 25684180
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic and prognostic significance of overexpression of her-2/neu and p53 oncoproteins in gastric carcinoma using tissue microarray.
Ismail HM; Moneer M; El-Baradie M; Khorshid O; Touny A
J Egypt Natl Canc Inst; 2007 Jun; 19(2):147-57. PubMed ID: 19034345
[TBL] [Abstract][Full Text] [Related]
8. Signal transduction proteins in tumors from Puerto Rican and Caucasian gastric adenocarcinoma patients: expression differences with potential for specific targeted therapies.
Cangiano J; Centeno BA; Garrett CR; Cáceres W; de Jesús A; Lee JH; Pavía O; Jove R; Báez L; Sullivan DM; Muro-Cacho CA; Muñoz-Antonia T
Dig Dis Sci; 2008 Aug; 53(8):2090-100. PubMed ID: 18224443
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic significance of HER-2/neu protein expression and gene amplification in gastric carcinoma.
Yan SY; Hu Y; Fan JG; Tao GQ; Lu YM; Cai X; Yu BH; Du YQ
World J Gastroenterol; 2011 Mar; 17(11):1501-6. PubMed ID: 21472111
[TBL] [Abstract][Full Text] [Related]
10. HER-2/neu amplification is an independent prognostic factor in gastric cancer.
Park DI; Yun JW; Park JH; Oh SJ; Kim HJ; Cho YK; Sohn CI; Jeon WK; Kim BI; Yoo CH; Son BH; Cho EY; Chae SW; Kim EJ; Sohn JH; Ryu SH; Sepulveda AR
Dig Dis Sci; 2006 Aug; 51(8):1371-9. PubMed ID: 16868827
[TBL] [Abstract][Full Text] [Related]
11. Correlations of β-catenin, Ki67 and Her-2/neu with gastric cancer.
Wu HW; Qin CY; Huang JL; Kong XY; Wang WJ; Bai WK
Asian Pac J Trop Med; 2014 Apr; 7(4):257-61. PubMed ID: 24507671
[TBL] [Abstract][Full Text] [Related]
12. Analysis of epithelial-cadherin and human epidermal growth factor receptor 2/ expression in gastric carcinoma using immunohistochemistry.
Dewan K; Madan R; Sengupta P; Bharadwaj R
Indian J Pathol Microbiol; 2015; 58(2):154-7. PubMed ID: 25885125
[TBL] [Abstract][Full Text] [Related]
13. [Immunohistochemical study of p53, c-erbB-2 and nm23 proteins in human gastric cancer].
Wei Z; Wu Y; Zhai Z
Zhonghua Zhong Liu Za Zhi; 1997 Sep; 19(5):378-81. PubMed ID: 10920922
[TBL] [Abstract][Full Text] [Related]
14. HER-2/neu overexpression is an independent prognostic factor for intestinal-type and early-stage gastric cancer patients.
Liu W; Zhong S; Chen J; Yu Y
J Clin Gastroenterol; 2012 Apr; 46(4):e31-7. PubMed ID: 22064554
[TBL] [Abstract][Full Text] [Related]
15. Comparison of c-erbB-2 oncoprotein expression in tissue and serum of patients with stomach cancer.
Chariyalertsak S; Sugano K; Ohkura H; Mori Y
Tumour Biol; 1994; 15(5):294-303. PubMed ID: 7991990
[TBL] [Abstract][Full Text] [Related]
16. Prognosis significance of HER-2/neu overexpression/amplification in Chinese patients with curatively resected gastric cancer after the ToGA clinical trial.
Zhou F; Li N; Jiang W; Hua Z; Xia L; Wei Q; Wang L
World J Surg Oncol; 2012 Dec; 10():274. PubMed ID: 23249720
[TBL] [Abstract][Full Text] [Related]
17. [Association of HER-2/neu expression with prognosis of gastric cancer].
Chen B; Luo RC; Cui F; Qian XY
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Mar; 26(3):344-7. PubMed ID: 16546744
[TBL] [Abstract][Full Text] [Related]
18. Serum HER2 levels and HER2 status in tumor cells in advanced gastric cancer patients.
Sasaki T; Fuse N; Kuwata T; Nomura S; Kaneko K; Doi T; Yoshino T; Asano H; Ochiai A; Komatsu Y; Sakamoto N; Ohtsu A
Jpn J Clin Oncol; 2015 Jan; 45(1):43-8. PubMed ID: 25378649
[TBL] [Abstract][Full Text] [Related]
19. HER-2/neu and TOPIIa expression in gastric cancer reflect disease severity.
Liu HQ; Zhang SL; Song S
Hepatogastroenterology; 2012 Jun; 59(116):1290-3. PubMed ID: 22281973
[TBL] [Abstract][Full Text] [Related]
20. Is Helicobacter Pylori associated with Her2/neu Overexpression in Gastric Cancer Patients who Underwent Curative Resection?
Yoo MW; Han HS; Kim SY; Cho YH; Lee HG; Kim JH; Bang HY; Lee KY; Yoon SY
Hepatogastroenterology; 2014 May; 61(131):858-62. PubMed ID: 26176087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
